+1-888-308-5802     
Industry Categories News Contact Us

Cipla agrees to buy U.S.-based Avenue Therapeutics in a $215m deal

Author : Pankaj Singh | Published Date : 2018-11-14 

Pharmaceutical drug giant Cipla recently confirmed that its U.S.-based subsidiary, InvaGen Pharmaceuticals, Inc. has signed definitive agreements for acquiring specialty pharmaceutical company Avenue Therapeutics, also from the U.S. The deal is reported to be valued at US$ 215 million (approx. Rs 1,560 crore).

A Fortress Biotech company, Avenue Therapeutics, Inc. is focused on developing and commercializing the painkiller intravenous (IV) Tramadol. Cipla informed in its statement that the company aims to acquire Avenue Therapeutics in two stages.

According to the company, InvaGen or its affiliates would acquire shares amounting to a 33.3 percent stake in Avenue’s capital stock for US$35 million on a fully diluted basis. This will be achieved by the issuance of new shares by Avenue, the company mentioned. At the same time, with the stock issuance closing, three members will be appointed by InvaGen or affiliates, including one independent member, on the seven-member board of directors of Avenue.

The second stage would involve InvaGen or its affiliates acquiring the remaining common stock shares of Avenue for up to US$180 million in the aggregate. The closing of the second stage is subject to certain conditions, such as those associated with USFDA approval and the absence of restrictions pertaining to IV Tramadol, including Risk Evaluation and Mitigation Strategy (REMS), Cipla mentioned.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said that the company’s investment in the proposed purchase of Avenue would help establish its presence in the US specialty business market. It aligns with Cipla’s intention to develop a specialty drug pipeline in the country, he added.

The company said this transaction would be subject to the approval from stockholders of Avenue Therapeutics and regulatory approvals, besides other closing conditions. Market reports show that Cipla shares were trading at Rs 528.25 per share on BSE at the time, down by 0.69 percent.

About Author

Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With experience in technical and niche writing, he was encouraged to opt for a career in content writing and now pens down articles pertaining to market research, industry news and business trends.

He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

UK supermarkets issue recall for items reported to pose health risks

Published Date: 2018-11-19         Author: Pankaj Singh

Reports confirm that major supermarkets including Asda, Lidl, Sainsbury’s, Tesco and Waitrose have discovered problems with some food items they sell which could mean a health risk for consumers. Customers are being asked to return these items to the stores for a full refund, said sources fami... Read More

IBM looks to boost scientific research using blockchain technology

Published Date: 2018-11-12         Author: Pankaj Singh

U.S. information technology giant IBM is reportedly planning to apply blockchain technology to help scientific research and to make available a record of its results. Sources with the knowledge of the matter informed that the company has recently filed a new patent application with the U.S. Patent a... Read More

Grab partners with Kasikornbank to launch mobile wallet in Thailand

Published Date: 2018-11-10         Author: Pankaj Singh

Ride-hailing company Grab recently made an announcement confirming that it has entered into a strategic partnership with Kasikornbank (KBank), the Thai lender, to bring its mobile wallet GrabPay and other related financial services into Thailand by early 2019. GrabPay, a co-branded mobile payment ap... Read More

© 2018 Fractovia. All Rights Reserved